Crystal Research Associates Discusses HIV Vaccine and H1N1 Flu Vaccines

Strategic Insights

Sep 23, 2009 — 1 min read

Crystal Research Associates' chief executive officer and cofounder, Jeffrey Kraws, was recently interviewed by Bloomberg Television, discussing the progress of a potential HIV vaccine in clinical testing and the challenges facing the development of H1N1 flu vaccines. Mr. Kraws highlighted recent advancements in vaccine technologies at biotechnology companies such as CEL-SCI Corporation, Generex Biotechnology Corporation, and Unilife Medical Solutions Limited. These advancements could supplement the research conducted by larger pharmaceutical companies.

Key Takeaways:

Crystal Research Associates' Jeffrey Kraws discussed the progress of a potential HIV vaccine in clinical testing on Bloomberg Television.
Kraws highlighted the advancements in vaccine technologies at biotechnology companies CEL-SCI Corporation, Generex Biotechnology Corporation, and Unilife Medical Solutions Limited.
These advancements could help supplement the research and development conducted by larger pharmaceutical companies.
The interview showcased the importance of vaccine technologies in addressing global health challenges.
Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto.
The company's unique product, the Executive Informational Overview (EIO), presents detailed reports on companies' product/technology/service offerings, market size(s), and growth strategy.

Statistics:

The HIV vaccine in clinical testing is a potential solution to addressing the global health challenge of HIV/AIDS.
The H1N1 flu vaccines are currently facing challenges in their development process.
CEL-SCI Corporation has been working on developing vaccine technologies for various diseases, including cancer and infectious diseases.
Generex Biotechnology Corporation has been developing oral insulin for the treatment of type 1 diabetes and other diseases.
Unilife Medical Solutions Limited has been developing needle-free injection systems for various applications.

Sources:

Bloomberg Television
COMTEX
BAYSTREET NEWSWIRE
Surface SmarTrend(R) Alert
SmarTrend Bulletin

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients